demonstrated suggested inconclusive safety concern ongoing study display ongoing demontrated benefit only observational study
COVID-19 severe or critically
COVID-19 severe or critically
antiviral and associated therapy
azithromycin COALITION II Covid-19 Brazil ...
chloroquine and derivatives Karolyi
hydroxychloroquine Mahevas Sarhan Yu HYDRA ... REMAP-CAP-HCQ Sarhan
favipiravir Kocayigit H
hydroxychloroquine plus macrolides Huang
ivermectin Okumuş Galan Galan Camprubi
lopinavir/ritonavir REMAP-CAP ... Cao
Lopinavir/ritonavir plus hydroxychloroquine REMAP-CAP ...
remdesivir CAP-China ...
sofosbuvir and daclatasvir Eslami

7 studies excluded by filtering options 2

5209 SIMPLE (Grein), 0 2300excludednot a RCTrisk of bias not avaialble
5226 Duke university (Hydroxychloroquine), 2020 210excludedrisk of bias not avaialble
5259 Duke University azithromycin, 2020 210excludedrisk of bias not avaialble
6184 Erdem, 2020 2110excludednot a RCTrisk of bias not avaialble
6262 Yamamura, 2020 2300excludednot a RCTrisk of bias not avaialble
6267 Murohashi, 2020 2100excludednot a RCTrisk of bias not avaialble
6368 Niaee (vs placebo), 2020 213excludedhigh risk of bias